Advocacy intelligence hub — real-time data for patient organizations
Azacitidine: FDA approved
Treatment of pediatric patients aged one month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML)
Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
National Cancer Institute (NCI) — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Inqovi
(CEDAZURIDINE AND DECITABINE)Orphan drugTaiho Pharmaceutical Co., Ltd.
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Decitabine is a nucleoside metabolic inhibitor that is believed to exert its effects after phosphorylation and direct incorpo...
Hagop Kantarjian, MD, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Elliot Stieglitz
Children's Hospital of Alabama
📍 Birmingham, Alabama
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Farhad Ravandi-Kashani, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Abhay Singh, MD, MPH
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute
📍 Cleveland, Ohio
Bart Scott
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA